Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance

Patent metadata

Field	Value
Publication number	US-11459388-B2
Application number	US-202017121065-A
Country	US
Kind code	B2
Filing date	Dec 14, 2020
Priority date	Oct 24, 2014
Publication date	Oct 4, 2022
Grant date	Oct 4, 2022

Abstract

Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.

First claim

What is claimed is:

1. A method of inducing phagocytosis of a target hematologic cancer cell, the method comprising:
contacting a target hematologic cancer cell with a macrophage in the presence of an antibody that specifically binds to leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) and does not activate signaling through LILRB1 upon binding, and an antibody that binds to the target hematologic cancer cell and thereby opsonizes the target cell, for a period of time sufficient to induce phagocytosis of the target cell by the macrophage.

2. The method of claim 1 , wherein the hematologic cancer is a leukemia.

3. The method of claim 2 , wherein the leukemia is acute myeloid leukemia (AML).

4. The method of claim 2 , wherein the leukemia is acute lymphoblastic leukemia (ALL).

5. The method of claim 2 , wherein the leukemia is chronic myeloid leukemia (CML).

6. The method of claim 2 , wherein the leukemia is chronic lymphocytic leukemia (CLL).

7. The method of claim 1 , wherein the hematologic cancer is a lymphoma.

8. The method of claim 7 , wherein the lymphoma is Hodgkin lymphoma.

9. The method of claim 7 , wherein the lymphoma is non-Hodgkin lymphomas (NHL).

10. The method of claim 9 , wherein the lymphoma is diffuse large B-Cell lymphoma.

11. The method of claim 9 , wherein the lymphoma is follicular lymphoma.

12. The method according to claim 1 , wherein the contacting is in vitro or ex vivo.

13. The method according to claim 1 , wherein the contacting is in vivo.

14. The method according to claim 7 , wherein said contacting is in the presence of an antibody that specifically binds to CD47 and blocks interaction of CD47 and SIRPa.

15. The method according to claim 1 , wherein the antibody that binds to the target cell binds to CD20.

16. The method according to claim 15 , wherein the antibody is rituximab, tositumomab or ibritumomab.

17. The method according to claim 1 , wherein the antibody that binds to the target cell binds to CD52.

18. The method of claim 16 , wherein the antibody is alemtuzumab.

19. The method according to claim 1 , wherein the antibody that binds to the target cell binds to CD22.

20. The method according to claim 1 , wherein the antibody that binds to the target cell is gemtuzumab.

Assignees

• Univ Leland Stanford Junior

Inventors

• Maute Roy Louis
• Weiskopf Kipp Andrew
• Ring Aaron Michael
• Weissman Irving L

Classifications

• A61B2017/00893

  pharmaceutically effective · CPC title

• A61F2210/0085

  hardenable in situ, e.g. epoxy resins · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• C07K16/2833 Primary

  against MHC-molecules, e.g. HLA-molecules · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title